Formosa Pharmaceuticals Grants Rxilient Rights to New Ophthalmic Drug
Taiwan-based Formosa Pharmaceuticals (6838.TW) has entered into an exclusive licensing agreement with Singapore-headquartered Rxilient Medical Pte. Ltd., granting the company…
Read More...
Read More...
